You have 9 free searches left this month | for more free features.

EBV

Showing 1 - 25 of 793

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection Trial in Beijing (EBV-TCR-T cells)

Recruiting
  • EBV-associated Hemophagocytic Lymphohistiocytosis
  • EBV Infection
  • EBV-TCR-T cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Nov 12, 2023

EBV Infection After Allogenic HSCT Trial in Beijing (EBV-TCR-T cells)

Recruiting
  • EBV Infection After Allogenic HSCT
  • EBV-TCR-T cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Nov 3, 2023

EBV-associated Lymphomas Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell

Not yet recruiting
  • EBV-associated Lymphomas
  • (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
  • (no location specified)
May 31, 2023

EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) Trial in Switzerland (Donor-derived ex-vivo expanded EBV Tscm

Not yet recruiting
  • EBV Lymphoma
  • Post-transplant Lymphoproliferative Disease (PTLD)
  • Donor-derived ex-vivo expanded EBV Tscm CTL
  • Basel, Switzerland
  • +7 more
Jan 25, 2023

Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus Trial run by the National Institute of Allergy and

Not yet recruiting
  • Epstein-Barr Virus Infection
  • +2 more
  • Matrix-M1 Adjuvant
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Hemophagocytic Lymphohistiocytoses, EBV, Metabonomics Trial in Beijing (observational)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytoses
  • +2 more
  • observational
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Dec 22, 2022

Reveals Relationship Between gp42-IgG Epitopes and

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Epitope exploration
  • (no location specified)
Jul 16, 2023

EBV-associated Haematologic Tumors Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed

Not yet recruiting
  • EBV-associated Haematologic Neoplasms
  • (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
  • (no location specified)
Dec 4, 2022

Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)

Recruiting
  • Epstein-Barr Virus Infections
  • +3 more
  • Nivolumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

Nasopharyngeal Carcinoma Trial in Wuhan (KSD-101)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • KSD-101
  • Wuhan, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 19, 2023

Nasopharyngeal Carcinoma Trial in Xuzhou (CAR-T Cell Injection, Fludarabine, cyclophosphamide)

Recruiting
  • Nasopharyngeal Carcinoma
  • CAR-T Cell Injection
  • +2 more
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 15, 2022

EBV-positive Nasopharyngeal Carcinoma Trial in Guangzhou (Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg,

Not yet recruiting
  • EBV-positive Nasopharyngeal Carcinoma
  • Cohort A: 3.0x10^6 CAR-T cells/kg
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 16, 2023

CMV Infection, EBV Infection, Stem Cell Transplant Trial (Virus specific T cells)

Not yet recruiting
  • CMV Infection
  • +2 more
  • Virus specific T cells
  • (no location specified)
Oct 4, 2023

Malignant Tumor Trial in Chendu (EBV immunological agent)

Recruiting
  • Malignant Tumor
  • EBV immunological agent
  • Chendu, Sichuan, China
    West China Hospital
Jan 31, 2023

HLH Trial in Beijing (Thiotepa)

Recruiting
  • HLH
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
May 10, 2023

EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis Trial run by the NIAID (EBV gp350-Ferritin Vaccine, Matrix-M1)

Recruiting
  • EBV
  • +2 more
  • EBV gp350-Ferritin Vaccine
  • Matrix-M1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 11, 2022

Nasopharyngeal Carcinoma Trial (PK Blood Collection, CAR, TCR)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • PK Blood Collection
  • +2 more
  • (no location specified)
Nov 1, 2022

Saliva EBV-DNA Detection in EBV Infection Related Diseases

Recruiting
  • EBV Infection
  • Saliva Testing
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 30, 2022

Epstein-Barr Virus Infection moniToring in renAl Transplant

Recruiting
  • EBV Infection
  • +3 more
  • EBV DNA in whole blood and plasma
  • Aarhus, Central Region Denmark, Denmark
  • +2 more
Dec 12, 2022

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease Trial in Houston (EBV-specific T cells: A, EBV-specific T

Recruiting
  • Hodgkin's Disease
  • +3 more
  • EBV-specific T cells: A
  • EBV-specific T cells: B
  • Houston, Texas
  • +1 more
Jun 28, 2022

Malignant Tumors Trial in Chengdu (EBV mRNA vaccine)

Recruiting
  • Malignant Tumors
  • EBV mRNA vaccine
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Jan 27, 2023

EBV-positive Gastric Cancer and Multiple Genes Associated With

Completed
  • Gastric Cancer
  • +2 more
  • Gastrectomy
  • Suwon, Gyeong-Gi-Do, Korea, Republic of
    Jiwon Seo
Oct 28, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)

Recruiting
  • Nasopharyngeal Carcinoma
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Mar 6, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Radiotherapy, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jan 7, 2023

EBV Emia and EBV Positive PTLD After Allogenic HSCT Trial in Sanhe (EBV-TCR-T cells)

Completed
  • EBV Emia and EBV Positive PTLD After Allogenic HSCT
  • EBV-TCR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022